Mechanism by Which Orally Administered β-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models

Feng Hong, Jun Yan, Jarek T. Baran, Daniel J. Allendorf, Richard D. Hansen, Gary R. Ostroff, Pei Xiang Xing, Nai-Kong V. Cheung and Gordon D. Ross

*This information is current as of July 24, 2018.


doi: 10.4049/jimmunol.173.2.797

http://www.jimmunol.org/content/173/2/797

References

This article cites 44 articles, 18 of which you can access for free at:
http://www.jimmunol.org/content/173/2/797.full#ref-list-1
Mechanism by Which Orally Administered β-1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models

Feng Hong,‡ Jun Yan,§ Jarek T. Baran,‖ Daniel J. Allendorf,* Richard D. Hansen,* Gary R. Ostroff,‡ Pei Xiang Xing,* Naikong V. Cheung,* and Gordon D. Ross†§

Antitumor mAb bind to tumors and activate complement, coating tumors with iC3b. Intravenously administered yeast β-1,3;1,6-glucans as an adjuvant for antitumor mAb by priming the inactivated C3b (iC3b) receptors (CR3; CD11b/CD18) of circulating granulocytes, enabling CR3 to trigger cytotoxicity of iC3b-coated tumors. Recent data indicated that barley β-1,3;1,4-glucan given orally similarly potentiated the activity of antitumor mAb, leading to enhanced tumor regression and survival. This investigation showed that orally administered yeast β-1,3;1,6-glucan functioned similarly to barley β-1,3;1,4-glucan with antitumor mAb. With both oral β-1,3-glucans, a requirement for iC3b on tumors and CR3 on granulocytes was confirmed by demonstrating therapeutic failures in mice deficient in C3 or CR3. Barley and yeast β-1,3-glucans were labeled with fluorescein to track their oral uptake and processing in vivo. Orally administered β-1,3-glucans were taken up by macrophages that transported them to spleen, lymph nodes, and bone marrow. Within the bone marrow, the macrophages degraded the large β-1,3-glucans into smaller soluble β-1,3-glucan fragments that were taken up by the CR3 of margined granulocytes. These granulocytes with CR3-bound β-1,3-glucan-fluorescein were shown to kill iC3b-opsonized tumor cells following their recruitment to a site of complement activation resembling a tumor coated with mAb. The Journal of Immunology, 2004, 173: 797–806.

Natural products useful in preventing or treating disease have been highly sought after throughout human history. A major problem in characterizing many natural products is that they represent a complex mixture of ingredients, each one of which may contribute to bioactivity. β-1,3;1,6-glucans from fungi (e.g., mushrooms) and yeast are well-known biologic response modifiers that function as immunostimulants against infectious diseases and cancer (1, 2). Unlike most other natural products, purified β-1,3-glucans retain their bioactivity. This has permitted the characterization of how β-1,3-glucans work on a cellular and molecular level.

Research with β-1,3;1,6-glucan from fungi, yeast, and seaweed, as well as β-1,3;1,4-glucan from barley, has shown that they function through stimulation of granulocytes (neutrophils and eosinophils), monocytes, macrophages, and NK cells. Two membrane β-1,3-glucan receptors that mediate biological responses to β-1,3-glucan have been characterized at a molecular level. The first to be reported was the inactivated C3b (iC3b)6 receptor known as CR3 (Mac-1, CD11b/CD18, or αMβ2 integrin) (3–5). CR3 is highly expressed on neutrophils, monocytes, and NK cells, whereas less is present on macrophages (6). Dectin-1 is the second β-1,3-glucan receptor to be described at a molecular level (7, 8). Dectin-1 is preferentially expressed on macrophages over granulocytes, while absent on NK cells (8). On macrophages, Dectin-1 is the dominant receptor mediating the phagocytosis of yeast (9), whereas CR3 performs this function with granulocytes (10, 11). Unique to CR3 are its two separate binding sites, one carbohydrate-binding site for β-1,3-glucan and a second site for the iC3b fragment of C3. The β-1,3-glucan-binding site is located within the C terminus of CD11b (4, 12), whereas iC3b-binding site maps to the N-terminal I-domain of the CD11b subunit of CR3 (13). Although the iC3b-binding function of CR3 allows it to bind avidly to iC3b-coated cells, CR3 is not triggered to mediate phagocytosis or cytotoxicity by ligation to cells bearing only iC3b. Activation of CR3 requires its dual ligation to both β-1,3-glucan and the iC3b deposited adjacent to the β-1,3-glucan on fungal cell walls by the complement system.

Mammalian cells do not produce β-1,3;1,6-glucans. Thus, iC3b-coated (opsonized) tumor cells are not killed by leukocytes via CR3. Nevertheless, CR3 mediates avid attachment of leukocytes to

6 Abbreviations used in this paper: iC3b, inactivated C3b; CR3, complement receptor type 3; the iC3b receptor also known as Mac-1, CD11b/CD18, or αMβ2 integrin; WGP, whole glucan particle, particulate β-1,3-glucan derived from baker's yeast; WGP-F, fluorescein-labeled WGP; WGP,F; fluorescein-labeled barley β-1,3-glucan, WGP,F; fluorescein-labeled WGP.
MECHANISM OF TUMOR REGRESSION MEDIATED BY ORAL β-GLUCAN

iC3b-coated tumor cells. An important finding was that soluble yeast β-1,3;1,6-glucan, as well as soluble barley β-1,3;1,4-glucan, bound to CR3 and primed the receptor to mediate leukocyte cytotoxicity of tumor cells coated with iC3b (5, 14). Cytotoxicity was blocked by anti-CR3 and did not occur with leukocytes from CR3-deficient mice. Moreover, β-1,3-glucan promoted this activity with human and mouse NK cells that express CR3 (5, 14, 15) but not Dectin-1 (8).

Intravenous injection of soluble yeast β-1,3-glucan into mice with mammary tumors resulted in regression of tumor growth. Tumor regression required natural antitumor Abs that bound to the tumors and activated complement with deposition of iC3b on the tumor cells. Therapy failed in SCID mice, which are missing B and T lymphocytes, but could be reconstituted by injection of natural Abs isolated from normal mouse serum. Therapy failures in C3- and CR3-deficient mice confirmed the requirement for iC3b on tumors and CR3 on leukocytes (16). Later studies showed that therapeutic efficacy could be enhanced significantly by injecting mice with complement-activating antitumor mAb that greatly increased the amount of tumor-bound iC3b. As expected, the efficacy of combining i.v. β-1,3-glucan with mAb was not observed in mice deficient in either C3 or CR3 (17).

In addition to these findings with i.v. β-1,3-glucan, there were also earlier reports that some mushroom β-1,3;1,6-glycans could mediate tumor regression when given orally (18, 19). In more recent studies using human tumor xenografts, orally administered soluble barley β-1,3,1,4-glucan or i.v. antitumor mAb were ineffective as single agents, but, when combined, elicited a substantial antitumor effect (20, 21). However, the mechanism by which large β-1,3-glycans could be taken up orally by the gastrointestinal tract and function to prime leukocyte CR3 was unknown.

The current investigation examined the mechanism of oral uptake of soluble barley and particulate yeast β-1,3-glucan and showed that these large β-1,3-glucans were taken up by gastrointestinal macrophages and shuttled to reticuloendothelial tissues and bone marrow. Within the marrow, the macrophages degraded the β-1,3-glucan and secreted small soluble biologically active fragments that bound to CR3 of mature bone marrow granulocytes. Once recruited from the bone marrow by an inflammatory stimulus, these granulocytes with β-1,3-glucan-primed CR3 could kill iC3b-coated tumor cells. As had been found earlier with i.v. soluble yeast β-1,3,1,6-glucan therapy, oral β-1,3-glucan-mediated tumor regression required the presence of iC3b on tumors and CR3 on granulocytes, and therefore failed in mice deficient in C3 or CR3.

Materials and Methods

Abs and other reagents

The hybridoma producing 14.G2a (IgG2a) anti-G102 mAb (22), was generously provided by Dr. R. Reisfeld (Research Institute of Scripps Clinic, La Jolla, CA). The BCP8 hybridoma producing IgG2b anti-human MUC1 mAb was previously described and is specific for the protein neoeptope revealed in underglycosylated MUC1 (23). The B5 hybridoma secreting mouse IgG2a mAb specific for the human high-molecular-mass melanoma Ag was obtained from the American Type Culture Collection (Manassass, VA) and used as a nonspecific mAb control for mouse tumor therapy protocols. Each hybridoma was grown in BioReactor flask (BD Biosciences, San Jose, CA) from which the mAb were purified as described previously (16, 17). Rat RB6-8CS anti-mouse-Gr-1-PE (anti-Gr-1-PE) and a PE-labeled isotype control were purchased from BD Pharmingen (San Diego, CA). Rat anti-mouse macrophage F4/80-PE-Cy5.5, as well as a PE-Cy5.5-labeled isotype control, were purchased from Caltag Laboratories (Burlingame, CA).

Therapeutic β-1,3-glucans

Whole glucan particles (WGP; Biopolymer Engineering, Eagan, MN) were purified from baker’s yeast through a series of alkaline and acid extractions to yield hollow yeast cell wall ghosts composed primarily of β-1,3;1,6-glucan (24). WGP were hydrated by addition to distilled water and sonicated to produce a single-particle suspension. The soluble yeast β-1,3;1,6-glucan known as neutral soluble glucan (NSG) β-1,3-glucan (Biopolymer Engineering) and its ability to bind to and prime CR3 were previously described (4, 5, 14, 17). Highly purified large-molecular-size barley β-1,3,1,4-glucan was prepared and characterized as previously described (21). Barley β-1,3-glucan was completely dissolved by boiling for 10 min in normal saline.

Mice and tumor models

The murine tumor therapy protocols were performed in compliance with all relevant laws and institutional guidelines, and were approved by the Institutional Animal Care and Use Committee of the University of Louisville. Normal C57BL/6 mice were purchased from National Cancer Institute (Frederick, MD). Colonies of C57BL/6 mice deficient in either C3 or CR3 (CD11b "−") and their wild-type (WT) littermates were generated and maintained for tumor therapy protocols as previously described (17). RMA-S-MUC1, a C57BL6 lymphoma cell line transfected with human MUC1 and its use in tumor therapy protocols in combination with 14.G2a anti-G102-ganglioside and β-1,3-glucan, were previously described (20).

C57BL/6 WT vs CR3-deficient mice were examined using the RMA-S-MUC1 tumor protocol with oral barley or WGP β-1,3-glucan in 16 groups of mice. For this protocol, one group of WT and one group of CR3-deficient mice were given oral PBS as a control for the oral β-1,3-glucans in water or saline. Two groups of WT or CR3-deficient mice received the same i.v. dose of 14.G2a and NSG β-1,3-glucan or 100 µg per i.v. dose every 3 days. Four groups of mice (two WT and two CR3-deficient) received either oral barley or oral WGP β-1,3-glucan, 400 µg per dose every day, beginning on the same day as the mAb therapy (preliminary experiments had shown that maximum tumor regression was obtained with a 400-µg daily dose of either barley or yeast WGP β-1,3-glucan). The final eight groups of mice received a combined i.v. 14.G2a mAb every third day and either oral barley or oral WGP β-1,3-glucan given daily, with the oral β-1,3-glucan administration beginning either on the same day that the i.v. mAb was administered or 3 days before administering the mAb.

Therapy was continued for 3 wk, with tumor diameter measurements made with calipers every third day, and mice were sacrificed if tumors reached 15 mm in diameter. Mice were observed for tumor-free survival over 90 days.

The generation of a Lewis lung carcinoma cell line transfected with human MUC1 (LL2-MUC1) and their use in tumor therapy protocols with BCP8 anti-MUC1 and β-1,3-glucan were previously described (17). Six groups of six C3-deficient and one group of C3-WT littermates (one each of 12 groups of mice) were treated with the following: 1) i.v. PBS every third day (control); 2) 100 µl of barley or yeast WGP β-1,3-glucan (4 mg/ml in saline or water; total, 400 µg) given daily using an intragastric gavage needle and syringe; 3) 200 µg of BCP8 anti-MUC1 mAb given every third day; 4) combined therapy with BCP8 mAb and oral barley or WGP β-1,3-glucan. Therapy was given for 3 wk with measurement of tumor diameters every third day, and mice were sacrificed when tumors reached 15 mm in diameter. Mice were observed over a period of 100 days for tumor-free survival.

Analysis of the fate of orally ingested barley and yeast WGP β-1,3-glucan

Barley and yeast WGP β-1,3-glucan were labeled with fluorescein using fluorescein dichlorotriazine (DTAF; Molecular Probes, Eugene, OR), which covalently reacts with hydroxyl groups of polysaccharides using a modification of the procedures suggested by the manufacturer. Briefly, 50 mg of barley β-1,3-glucan was diluted to 20 mg/ml with borate buffer (pH 10.8), and with mixed with 10 mg of DTAF dissolved in 0.5 ml of DMSO and heated for 1 h at 75°C. This generated a barley β-1,3-glucan gel that was pelleted by centrifugation and dissolved in 5 ml of 200 mM NaOH at 75°C. The DTAF-labeled barley β-1,3-glucan (BG-F) was then precipitated with ethanol. The pellet was dissolved in 200 ml of NaOH at 75°C, and the precipitate was washed by solubilization control. Several times until a clear supernatant free of unbound DTAF was obtained. After final solubilization in a small volume of NaOH, the BG-F was diluted in PBS to a concentration of 4 mg/ml, and the pH was adjusted to 7.2.

DTAF at 2 mg/ml was added to a suspension of yeast WGP β-1,3-glucan (20 mg/ml) in borate buffer (pH 10.8), and incubated at room temperature overnight with continuous stirring. Unbound DTAF was removed by centrifugation and washing the pelletted fluorescein-labeled WGP.
Analysis of in vitro macrophage degradation of ingested yeast WGP β-1,3-glucan

The murine macrophage line J774 (from the American Type Culture Collection) was plated at 1 × 10^6 cells per well of six-well plates in DMEM with 10% FCS, penicillin-streptomycin, and glucose, and after 16 h of culture, were incubated with WGP-F at a 1:10 particle-to-cell ratio at 37°C. Cultures without added WGP-F served as controls. Using fluorescence microscopy with a high-powered digital camera, some experiments, macrophages in spleen and bone marrow suspensions were enriched by absorption and EDTA elution from fibronectin-coated culture plates (BD Biosciences). In other experiments where noted, macrophages were identified in cell suspensions by staining with F4/80-PE-Cy5.5.

Analysis of splanic macrophage-mediated cytokotoxicity

Mice were fed 400 μg of barley β-1,3-glucan daily by intragastric gavage and sacrificed on sequential days for isolation of splenic macrophages prepared by finely mincing the spleens and passing the cells through a 70-μm strainer. Macrophages obtained from mice not given barley β-1,3-glucan served as a control for the effect of in vivo exposure to β-1,3-glucan. PTAS-64 murine mammary adenocarcinoma cells (17) were labeled with 111In at a ratio of 100 μCi per 10^6 cells and opsonized with 111In-anti-MMTV mAb (17) and fresh mouse serum as a source of complement to coat cells with iC3b (5). Macrophages and iC3b tumor cells were incubated in 96-well plates at E:T ratios ranging from 5:1 to 40:1 tested in triplicate for 4 h at 37°C. To demonstrate the requirement for CR3 in tumor killing, some samples were treated with M1/70 rat anti-mouse CR3 mAb (5).

Graphing and statistical analysis of data

Data from mouse therapy protocols were entered into Prism 4.0 (GraphPad Software, San Diego, CA) to generate graphs of tumor regression or survival and to determine the significance of differences between data sets. Student’s t test was used to compare differences between two tumor regression curves, whereas the log rank test was used to determine the significance of differences between two survival curves.

Results

The antitumor activity mediated by oral β-1,3-glucans requires C3 and CR3

Recent reports that examined tumor xenograft models had shown that orally administered barley β-1,3:1,4-glucan (20, 21) functioned in the same way as did i.v. soluble yeast β-1,3;1,6-glucan tested with syngeneic tumor models (17), with both routes of β-1,3-glucan administration enhancing the tumor regression activity of complement-activating antitumor mAb. Additional experiments showed that yeast β-1,3;1,6-glucan particles (WGP) given orally also potentiated antitumor mAb therapy. A similar requirement for complement in the tumor regression mediated by oral barley and yeast i.v. β-1,3-glucan had been suggested because tumor regression required use of complement-activating antitumor mAb (16, 17, 20), and therapy with an IgG1 mAb that did not activate complement was not enhanced by oral barley β-1,3-glucan (21). To determine whether oral β-1,3-glucan therapy had the same requirement for iC3b on tumors and CR3 on leukocytes as had been shown with i.v. yeast β-1,3-glucan therapy (16, 17), tumor therapy protocols were conducted comparing WT C57BL/6 mice to either CR3-deficient (CD11b^-/-) or C3-deficient (C3^-/-) C57BL/6 mice (Figs. 1-4).
The protocol used to compare WT to CR3-deficient mice used RMA-S-MUC1 tumor cells and 14.G2a anti-GD2 ganglioside mAb (Figs. 1 and 2). Groups of mice were given either oral barley or yeast WGP β-1,3-glucan on the same day as the mAb or 3 days before the mAb. With both β-1,3-glucans, earlier oral administration gave more rapid tumor regression, and therefore this early administration of oral β-1,3-glucan was used in subsequent protocols. However, after 3 wk of therapy, there was no difference in the regression resulting from giving the β-1,3-glucan at the earlier time point (Fig. 1). Treatment with mAb alone elicited no tumor regression, whereas combining the i.v. mAb with oral barley or yeast β-1,3-glucan elicited significantly enhanced tumor regression compared with that mediated by mAb alone. A small antitumor effect observed in mice treated with β-1,3-glucan alone was likely due to naturally occurring Ab to the parent LL/2 cells. By contrast, neither β-1,3-glucan given orally alone or in combination with mAb could elicit tumor regression in C3-deficient mice. In addition, both oral β-1,3-glucans, when combined with mAb, achieved 40% survival in WT mice vs no survival in C3-deficient mice (Fig. 5). Examination of tumors from mice that escaped the combined mAb plus β-1,3-glucan therapy showed that 75% of the tumor cells no longer expressed the MUC1 target Ag.

Oral β-1,3-glucans are ingested by macrophages that transport them to lymphoid organs

To determine the mechanism for oral uptake of β-1,3-glucan, both barley β-1,3-glucan and yeast WGP β-1,3-glucan were labeled with fluorescein (BG-F and WGP-F) and given to mice by intra-gastric injection in a manner similar to tumor therapy protocols. With the barley β-1,3-glucan, fluorescence microscopy revealed the generation of microaggregates by the DTAF fluorescein-labeling procedure. Groups of mice were sacrificed periodically and examined for BG-F and WGP-F in lymph nodes, spleen, and bone.
macrophage degradation of all visible cytoplasmic β-1,3-glucan-F required >13 days. Typically ingested WGP-F particles remained intact for 3–5 days, appeared to fragment into smaller particles and soluble material (5–10 days), and the intracellular fluorescence disappeared after 14–21 days. During this time, there was complete concordance in the amounts of biologically active β-1,3-glucan and fluorescein in culture supernatants. Moreover, the β-1,3-glucan bioactivity and fluorescein were retained during concentration of the supernatants with a 3-kDa molecular mass cutoff membrane that would have allowed the passage of small β-1,3-glucan-F oligosaccharides or unbound fluorescein. These data indicated that macrophages degrade large molecules of barley or yeast β-1,3-glucan into smaller biologically active fragments of β-1,3-glucan that are released into the medium.

Although all the bone marrow cells containing ingested β-1,3-glucan-F were initially shown to be macrophages identified by F4/80-PE-Cy5.5 staining (Fig. 5, E, F, and H), nonmacrophage (F4/80-negative) cells bearing membrane fluorescein staining began to appear in the bone marrow by day 5 of oral yeast WGP-F administration (G). Morphologically, these cells appeared to be granulocytes, and they were observed only in the bone marrow of WT and not CR3-deficient mice. To determine whether the soluble β-1,3-glucan-F released by macrophages had indeed been taken up by bone marrow granulocytes, groups of WT or CR3-deficient mice that had been given WGP-F or BG-F for 10 days were injected i.p. with thioglycolate medium to elicit the marginated pool of bone marrow granulocytes into the peritoneal cavity. Although the majority of peritoneal cells recruited by 4-h thioglycolate treatment are granulocytes, the elicited cells were stained with anti-Gr-1-PE to confirm their identification as granulocytes (Fig. 7). Granulocytes elicited from mice that had not been administered WGP-F or BG-F served as negative controls for fluorescein staining. This experiment detected significantly more membrane-bound fluorescein on WT than on CR3-deficient granulocytes. The enhanced granulocyte staining of cells bearing CR3, along with the finding that the fluorescein released from cultured macrophages corresponded to soluble β-1,3-glucan, indicated that the fluorescein...
staining represented membrane-bound β-1,3-glucan-F, which was predominantly attached to CR3. This conclusion is supported by previous research showing that soluble β-1,3-glucan-F added to peritoneal neutrophils in vitro was bound to the surface of WT but not CR3-/- neutrophils (5). Thus, these data support a mechanism of oral β-1,3-glucan activity involving the sequential ingestion of β-1,3-glucan by gastrointestinal macrophages that shuttle the β-1,3-glucan to the bone marrow where soluble degradation fragments are released and taken up by granulocytes via membrane CR3.

Granulocytes with CR3-bound β-1,3-glucan are able to kill iC3b-coated tumors

Tumors that activate complement via the binding of antitumor Abs are thought to become inflammatory foci through the release of the chemotactic factor C5a that functions to recruit the marginated pool of granulocytes, as well as tissue macrophages. Peritoneal granulocytes elicited in response to thioglycollate are a model of complement-mediated granulocyte recruitment. This experiment examined the hypothesis that granulocytes primed with CR3 surface-bound β-1,3-glucan could be recruited by tumors that had activated complement, thereby allowing them to recognize and kill tumor cells coated with iC3b. Elicited peritoneal granulocytes were isolated from WT and CR3-deficient mice that had been given oral β-1,3-glucan and tested for their ability to kill iC3b-coated tumor cells in vitro. Granulocytes from mice that had not been given oral WGP β-1,3-glucan served as a control for the ability of non-glucan-exposed granulocytes to kill iC3b-coated tumor cells (Fig. 8). The data indicated that WT granulocytes with CR3-bound β-1,3-glucan could kill significantly more iC3b tumor cells than WT granulocytes from mice not given oral β-1,3-glucan. The requirement for CR3 was confirmed by the significantly reduced tumor-killing activity by granulocytes from CR3-deficient mice that had been given oral β-1,3-glucan. The relatively low level of cytotoxicity elicited with WT granulocytes (12%) appeared to correspond to the low proportion of peritoneal granulocytes that exhibited CR3 surface-bound β-1,3-glucan-F, i.e., ~16% (Fig. 7). This hypothesis was confirmed by showing that the cytotoxicity of elicited WT, but not CR3-deficient granulocytes, could be significantly enhanced by the addition of exogenous soluble yeast β-1,3-glucan (Fig. 8).

To determine whether the soluble β-1,3-glucan secreted by macrophages similarly mediated CR3-dependent granulocyte cytotoxicity, a BioReactor system with J774 cell-coated microcarrier beads was used to generate soluble β-1,3;1,6-glucan derived from ingested WGP. Cytotoxicity assays indicated that this macrophage-derived β-1,3-glucan produced maximum levels of cytotoxicity when used at a hexose concentration of 1.0 μg/ml (Fig. 8). In comparison to the only currently available preparation of NSG, the macrophage-derived β-1,3-glucan when used at a concentration of 0.5 μg/ml elicited approximately the same level of cytotoxicity as did 10 μg/ml NSG β-1,3-glucan (not shown). As expected, the

FIGURE 3. Tumor regression with orally administered soluble barley or particulate yeast β-1,3-glucan requires serum C3. Groups of WT or C3-deficient C57Bl/6 mice were implanted s.c. with LL/2-MUC1 and after 7 days were treated with i.v. BCP8 anti-MUC1 with or without simultaneous oral barley or yeast β-1,3-glucan (WGP). Mean values ± SD are shown.
mechanism. Although i.v. soluble NSG together with either oral or i.v. tumor regression and yet mediated complete remission when given.

Additional experiments demonstrated that splenic macrophages from mice given oral barley β-1,3-glucan daily acquired the ability to kill iC3b tumor cells after 3 days, and that all tumor-killing activity was inhibited completely by an anti-CR3 mAb (data not shown). In conclusion, these experiments show that bone marrow granulocytes and tissue macrophages acquire membrane CR3-bound soluble β-1,3-glucan from gastrointestinal macrophages, and that this bound β-1,3-glucan primes the CR3 of both granulocytes and macrophages so that, when they are recruited to a site of inflammation, they are able to kill iC3b-coated tumor cells.

Discussion

β-1,3-Glucan functions as a potent adjuvant for mAb therapy of cancer to elicit a novel granulocyte- and tissue macrophage-mediated tumor-killing mechanism that is not activated by mAb therapy alone. Various tumor models were described in this and previous reports in which specific mAb given alone had little or no effect on tumor regression and yet mediated complete remission when given together with either oral or i.v. β-1,3-glucan (16, 17, 20, 21). This study showed that oral and i.v. β-1,3-glucans function by a similar mechanism. Although i.v. soluble NSG β-1,3-glucan is delivered directly to the CR3 on circulating granulocytes, orally administered β-1,3-glucan goes through an intermediate step in which macrophages process and deliver soluble β-1,3-glucan to the CR3 of granulocytes in the bone marrow. In addition to priming granulocyte CR3, oral β-1,3-glucan primes the CR3 of tissue macrophages and probably also the CR3 of marrow monocytes and NK cells, although these other marrow leukocyte types were not examined.

A variety of fungal and yeast (1,3;1,6-linked β-glucose) and cereal grain (1,3;1,4-linked β-glucose) β-1,3-glucans have been reported to have antitumor activity. Most animal experimentation and clinical trials have tested fungal β-1,3-glucan such as lentinan or schizophyllan given i.v. (26–28). Notably, there have also been reports that some mushroom β-1,3-glucans functioned against cancer when given orally (18, 28–31). The current investigation showed that oral uptake and biodistribution of barley or yeast β-1,3-glucan occurred via gastrointestinal macrophages.

Current and previously reported data (16, 17, 20) show that β-1,3-glucan-mediated tumor regression requires antitumor Abs that activate complement and deposit iC3b on the tumor cells. Tumor regression elicited with β-1,3-glucan alone has been shown to be due to naturally elicited antitumor Abs that function similarly to exogenous antitumor mAb by coating tumors with iC3b. The absence of antitumor Ab in some animal tumor models, and particularly in some cancer patients, explains the inconsistent responses observed with β-1,3-glucan monotherapy. In addition to functioning with antitumor mAb, vaccines that elicit antitumor Abs are potentiated by β-1,3-glucan. Notably, a MUC1 peptide vaccine that elicited a strong Ab response but no protection from challenge with a MUC1+ tumor (32) was completely protective when the tumor challenge was conducted in MUC1-immunized mice given oral β-1,3-glucan (G. D. Ross, unpublished observation). Moreover, a different vaccine formulation that elicited primarily a non-complement-activating IgG1 response was not protective when combined with β-1,3-glucan.

Four humanized antitumor mAb, Herceptin (Trastuzumab, specific for Her2/neu) (33, 34), Rituxan (Rituximab, specific for CD20) (35, 36), Campath-1H (Alemtuzumab, specific for CD52) (37, 38), and Erbitux (Cetuximab, specific for Her1/EGFR) (39, 40), are now being used to treat patients with metastatic breast carcinoma, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and metastatic colon carcinoma, respectively. Rituxan kills tumors by several mechanisms including Ab-dependent cellular

![FIGURE 4](http://www.jimmunol.org)
cytotoxicity and complement-dependent cytotoxicity, and can induce major clinical responses. Nevertheless, when Rituxan was given in combination with oral β-1,3-glucan in a murine xenograft model, tumor regression was significantly enhanced (20).

Herceptin and Erbitux have demonstrated only modest (~20%) responses when used as monotherapy. Both mAb function only against tumor cells that overexpress the Her2 or Her1 growth factor receptors, respectively, and only if the patient’s tumor relies entirely on the growth factor receptor for survival. Both Herceptin and Erbitux contain the human IgG1 Fc region to facilitate complement activation with deposition of iC3b on tumor cells bearing the target Her2 or Her1 Ags (41, 42). In mouse xenograft models, although there was no tumor regression response mediated by Herceptin or Erbitux alone, significant regression was observed when the mAb were given in combination with oral β-1,3-glucan (20).

This investigation showed that oral β-1,3-glucan therapy was likely dependent on two types of β-1,3-glucan receptors. First, the uptake of barley and yeast WGP-β-1,3-glucan by gastrointestinal macrophages occurred with CR3-deficient mice, suggesting the likely involvement of Dectin-1 (2, 9). Second, bone marrow granulocytes used CR3 to take up the soluble β-1,3-glucan released by macrophages that had partially degraded either barley or yeast WGP-β-1,3-glucan. The finding of CR3 surface-bound β-1,3-glucan on isolated peritoneal granulocytes represents the first demonstration that membrane CR3 serves as a receptor for β-1,3-glucan.
in vivo. Although macrophages and granulocytes may also use Dectin-1 to capture soluble β-1,3-glucan, only CR3 with bound β-1,3-glucan triggers cytotoxic degranulation in response to iC3b-coated tumors (5, 14, 15). Splenic macrophages from mice given oral barley β-1,3-glucan also used CR3 to kill iC3b-tumor cells. The requirement for CR3 on leukocytes and iC3b on tumors was highlighted by demonstration of therapy failures in mice deficient in either CR3 or C3. Nevertheless, there was a low level of β-1,3-glucan-mediated tumor regression and survival in CR3<sup>−/−</sup> mice treated with oral WGP β-1,3-glucan (but not barley β-1,3-glucan) that suggests a minor role for non-CR3 β-1,3-glucan receptors in tumoricidal activity. The reduced level of tumoricidal activity observed with granulocytes from CR3<sup>−/−</sup> mice given oral WGP β-1,3-glucan or treated in vitro with soluble β-1,3-glucan (Fig. 8) may also be due to a non-CR3-dependent pathway of cytotoxicity.

Analysis of peritoneal granulocytes from mice that had received oral fluorescein-labeled barley or yeast WGP β-1,3-glucan showed that 16–24% of cells bore surface-bound β-1,3-glucan-fluorescein. Tests of these granulocytes for cytotoxicity of iC3b-tumor cells revealed a low-but-significant level of CR3-dependent cytotoxicity compared with granulocytes from mice that had not been given β-1,3-glucan. Because soluble β-1,3-glucan is reversibly bound to CR3 (4), it is likely that, over the 4 h during which granulocytes were elicited to the peritoneal cavity, some of the CR3-bound β-1,3-glucan-fluorescein may have dissociated from the cell surface. Addition of soluble β-1,3-glucan to elicited peritoneal granulocytes in vitro generated a significant enhancement in their CR3-dependent killing of iC3b-tumor cells, confirming that the initial lower level of CR3-dependent tumoricidal activity was due to a partial priming of CR3 with β-1,3-glucan in vivo. Despite what appears to be minimal cytotoxicity mediated by elicited granulocytes in vitro, the essential role of granulocytes in oral, as well as i.v. (17), β-1,3-glucan therapy was confirmed by showing complete inhibition of tumor regression activity in mice depleted of granulocytes with anti-Gr-1 mAb (G. D. Ross, unpublished data). Thus, even though the CR3 of macrophages are primed in vivo with β-1,3-glucan, the tumoricidal activity of macrophages is insufficient to mediate tumor regression without granulocytes. The previous demonstration that antitumor mAb plus β-1,3-glucan is equally effective in SCID or nude mice as compared with WT mice, also indicates that this mechanism of tumor rejection does not require T cells (16, 20, 21). Depletion of NK cells also had no effect on tumor regression (21). Nevertheless, the predominant role of granulocytes has been demonstrated only with s.c. tumors, and thus it remains possible that tumors in other anatomic locations may be more effectively killed by macrophages. For example, the gastrointestinal macrophages that have taken up oral β-1,3-glucan may be more effective against nearby gastrointestinal tumors than against distant s.c. tumors that granulocytes may be able to reach more quickly via the blood.

This research provides the basis for clinical trials that have recently been initiated in which patients are treated with antitumor mAb and oral β-1,3-glucan. Therapy with mAb or vaccines in combination with β-1,3-glucan offers several advantages over immunotherapy protocols designed to elicit immune CTL. First, it is usually easier to elicit an Ab response than a CTL response with a tumor vaccine. Second, the choice of tumor Ags includes carbohydrates and gangliosides, and is not limited to specific peptide sequences that can be presented by MHC class I molecules. Third, metastatic tumors cannot escape immune recognition by downregulating their expression of MHC class I as occurs frequently with CTL responses (43–45). Fourth, β-1,3-glucan therapy can use humanized mAb to target tumors and thus does not rely on the patient’s own immune response, which is frequently suppressed because of tumor burden and/or previous chemoradiation therapy. Nevertheless, the use of antitumor mAb and β-1,3-glucan should not interfere with the function of CTL-based immunotherapy, and the targeting of tumors simultaneously with both CTL and granulocytes should provide a more effective means of eliminating tumors and developing a long-term tumor-specific immunity that prevents tumor recurrence.

Acknowledgments

We are grateful for the donations of hybridomas, as well as tumor cell lines, from Drs. Ian F. C. McKenzie, Ralph Reisfeld, and Olivia Finn. We particularly thank Steve Lipinski and Malcolm Finkelman at Associates of Cape Cod for their help in performing the Glucatell assays. We also thank Dr. Tanya Mayadas-Norton for providing the breeding colony of CR3-deficient mice, and Dr. Magda Kucia for help in preparing the photomicrographs of WGP-F- and BG-F-containing macrophages (Fig. 5).

References

1. Borchers, A. T., J. S. Stern, R. M. Hackman, C. L. Keen, and M. E. Gershwin. 1999. Mushrooms, tumors, and immunity. Proc. Soc. Exp. Biol. Med. 221:281.

FIGURE 8. Granulocytes from WT mice that had been given daily oral doses of yeast WGP β-1,3-glucan for 10 days were able to kill iC3b-opsonized tumor cells significantly better than were granulocytes from CR3-deficient mice given the same oral doses of WGP β-1,3-glucan. Peritoneal granulocytes were isolated from WT or CR3-deficient mice that had received daily oral doses of WGP β-1,3-glucan and tested for their ability mediate cytotoxicity of <sup>51</sup>Cr-labeled RMA-S-MUC1 tumor cells coated with iC3b. Data obtained with a 3:1 granulocyte-to-tumor cell ratio are shown. Granulocytes from WT mice that had not received oral β-1,3-glucan served as a control for the effect of the oral yeast WGP. To determine whether granulocytes had been fully primed by soluble β-1,3-glucan in vivo, granulocytes from both WT and CR3<sup>−/−</sup> mice that had been exposed to β-1,3-glucan in vivo through orally administered WGP β-1,3-glucan were additionally treated with 10 μg/ml soluble NGF β-1,3-glucan in vitro. Granulocytes from WT mice that had been primed in vivo by oral WGP β-1,3-glucan exhibited significantly more cytotoxicity (p < 0.01) than did granulocytes from either CR3<sup>−/−</sup> mice that had similarly been administered oral WGP β-1,3-glucan or WT mice that had not been exposed to β-1,3-glucan in vivo or in vitro. With granulocytes from WT mice that had been primed in vivo with orally administered WGP β-1,3-glucan, there was a significant increase in cytotoxicity produced by treating the granulocytes in vitro with NGF β-1,3-glucan (p < 0.0001). By contrast, there was no significant increase in cytotoxicity when granulocytes from CR3<sup>−/−</sup> mice primed in vivo with oral β-1,3-glucan were secondarily primed in vitro with NGF β-1,3-glucan. Soluble β-1,3-glucan secreted by cultured J774 macrophages that had ingested WGP β-1,3-glucan was 10–20 times more active on a weight basis in inducing WT granulocyte cytotoxicity than was this preparation of NGF β-1,3-glucan, but elicited only minimal cytotoxicity from CR3<sup>−/−</sup> granulocytes. The data shown represent the mean values and 1 SD from three experiments conducted in triplicate.
17. Hong, F., D. G. Ross, and S. Gordon. 2003. Fungal β-glucans and mammalian immunity. Immunity 19:311.

18. Ross, D. G., J. A. Cain, B. L. Myones, S. L. Newman, and P. J. Lachmann. 1987. Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement Immunol. 4:61.

19. Thornton, B. P., V. Vetvicka, M. Pitman, R. C. Goldman, and G. D. Ross. 1996. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1235.

20. Xia, Y., V. Vetvicka, J. Yan, M. Hanikyrova, T. N. Mayadas, and G. D. Ross. 1999. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytoytic action in response to iC3b-opsonized target cells. J. Immunol. 162:2284.

21. Ross, G. D. 2000. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/αβ₂-integrin glycoprotein. Crit. Rev. Immunol. 20:197.

22. Brown, G. D., and H. Y. Xavier. 2003. Fungal β-glucans and mammalian immunity. Immunity 19:311.

23. Xing, P. X., J. Prenzkoska, K. Quelic, and I. F. McKenzie. 1992. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res. 52:2310.

24. James, S., C. R. K. Rha, and A. J. Simskey. 1989. Glucan compositions and process for preparation thereof. U.S. Patent 4510646. Issued March 7, 1989.

25. Brown, G. D., J. H. Herre, D. L. Williams, J. A. Willment, A. S. Marshall, and S. Gordon. 2003. Dectin-1 mediates the biological effects of β-glucans. J. Exp. Med. 197:1119.

26. Taguchi, T. 1987. Clinical efficacy of lentian on patients with stomach cancer: end point results of a four-year follow-up survey. Cancer Detect. Prev. Suppl. 1:333.

27. Matsuoka, H., Y. Seo, H. Wakahsugi, T. Saito, and H. Tomoda. 1997. Lentian potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 17:2751.

28. Kidd, P. M. 2000. The use of mushroom glucans and proteoglycans in cancer treatment. Altern. Med. Rev. 5:4.

29. Tsukagoshi, S., Y. Hashimoto, G. Fuji, H. Kobayashi, K. Nomoto, and K. Orita. 1984. Krestin (PSK). Cancer Treat. Rev. 11:131.

30. Suzuki, I., K. Hashimoto, N. Ohno, H. Tanaka, and T. Yodogawa. 1989. Immunomodulation by orally administered β-glucan in mice. Int. J. Immunopharmacol. 11:761.

31. Nanba, H. 1995. Activity of maitake D-fraction to inhibit carcinogenesis and metastasis. Ann. NY Acad. Sci. 768:243.

32. Soares, M. M., V. Mehta, and D. J. Finn. 2003. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J. Immunol. 166:6555.

33. Leyland-Jones, B. 2002. Trastuzumab: hopes and realities. Lancet Oncol. 3:137.

34. Ransohoff, M., and M. J. Shlomowik. 2002. Perspectives on anti-HER monoclonal antibodies. Oncology 63(Suppl. 1):17.

35. Cerny, T., B. Borrich, M. Intraona, P. Johnson, and A. L. Rose. 2002. Mechanism of action of rituximab. Anticancer Drugs 13(Suppl. 2):S3.

36. Johnson, P., and M. Glennie. 2003. The mechanisms of action of rituximab in the elimination of tumor cells. Semin. Oncol. 30:3.

37. Waldmann, H. 2002. A personal history of the CAMPATH-1H antibody. Med. Oncol. 19(Suppl. 1):S3.

38. Keating, M. J., I. Flinn, V. Jain, J. L. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, and K. R. Rai. 2002. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99:3554.

39. Herbst, R. S., and D. M. Shin. 2002. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1393.

40. Mendelsohn, J. 2002. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20:18.

41. Sliwowski, M. X., J. A. Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. Fox. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60.

42. Spiridon, C. I., M. A. Ghetie, J. Uhr, R. Marches, J. L. Li, G. L. Shen, and E. S. Vitteta. 2002. Targeting multiple her-2 epitopes with monoclonal antibodies results in improved antitumor activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8:720.

43. Sanda, M. G., N. P. Restifo, J. C. Walsh, Y. Kawakami, W. G. Nelson, D. M. Pardoll, and J. W. Simons. 1995. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87:280.

44. Porgador, A., O. Mandelboim, N. P. Restifo, and J. L. Strominger. 1997. Natural killer cell lines kill autologous β₂-microglobulin-deficient melanoma cells: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 94:13140.

45. Hicklin, D. J., Z. G. Wang, F. Arienti, L. Rivoltini, G. Parmiani, and S. Ferrone. 1998. β₂-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J. Clin. Invest. 101:2720.